COTA expands clinicogenomics offering with Genomic Testing Cooperative partnership.
Subscribe on your favorite platform:
Almost 10% of the world’s population suffers from a type of blood cancer. And despite popular opinion, there are actually hundreds of different types of blood cancer, not just leukemia and lymphoma.
But are we doing everything in our power when developing clinical trials to improve cancer treatment? Could we include diversity and make trials more accessible to everyone? Our guest today thinks we have more work to do in the blood cancer space.
In this episode of the Real World Talk podcast, our host Miruna Sasu welcomes Dr. Gwen Nichols, Executive Vice President and Chief Medical Officer of The Leukemia & Lymphoma Society (LLS). We discuss the importance of making clinical trials more diverse and feasible for patients. We also get into Dr. Gwen’s predictions for the future and why she thinks there’s hope for earlier cancer detection and prevention.